Intercalating and maintenance gefitinib plus chemotherapy versus chemotherapy alone in selected advanced non-small cell lung cancer with unknown EGFR status

Abstract Epidermal growth factor receptor tyrosine-kinase inhibitors (EGFR-TKIs) are standard treatment for advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation. However, EGFR mutation testing is not attainable in approximately 20% of patients. T...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hong Jian, Wei Li, Zhiyong Ma, Jianjin Huang, Jifeng Feng, Yong Song, Beili Gao, Huili Zhu, Min Tao, Chong Bai, Shenglin Ma, Hongming Pan, Shukui Qin, Dong Hua, Yongfeng Yu, Shun Lu
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/73a535d20751439e9652e1984861c8ac
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:73a535d20751439e9652e1984861c8ac
record_format	dspace
spelling	oai:doaj.org-article:73a535d20751439e9652e1984861c8ac2021-12-02T15:04:57ZIntercalating and maintenance gefitinib plus chemotherapy versus chemotherapy alone in selected advanced non-small cell lung cancer with unknown EGFR status10.1038/s41598-017-08399-82045-2322https://doaj.org/article/73a535d20751439e9652e1984861c8ac2017-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-08399-8https://doaj.org/toc/2045-2322Abstract Epidermal growth factor receptor tyrosine-kinase inhibitors (EGFR-TKIs) are standard treatment for advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation. However, EGFR mutation testing is not attainable in approximately 20% of patients. The current study examined intercalating and maintaining gefitinib treatment in stage IIIB/IV non-squamous NSCLC, never or former light smoking patients with unknown EGFR mutation status. Briefly, 219 patients who achieved stable disease (SD) with gemcitabine (1250 mg/m2) plus carboplatin (5 AUC) were randomized at 1:1 ratio to continue chemotherapy (n = 110) or intercalating gefitinib (250 mg/day on days 15–25 of each cycle until disease progress (n = 109). Progression-free survival (PFS) was 9.7 vs. 4.2 month in the gefitinib vs. control arm (HR: 0.41, 95% CI: 0.31–0.56; P < 0.001). Overall survival (OS) was also longer in the gefitinib arm (20.1 vs. 15.4 months; HR: 0.68; 95% CI 0.48–0.97; P = 0.0323). Adverse events, including diarrhea, dermal reaction and thrombocytopenia, were more common in the gefitinib arm. In conclusion, intercalating and maintenance gefitinib treatment is a viable option for advanced NSCLC patients with unknown EGFR mutation status in subpopulations with high EFGR mutation rate.Hong JianWei LiZhiyong MaJianjin HuangJifeng FengYong SongBeili GaoHuili ZhuMin TaoChong BaiShenglin MaHongming PanShukui QinDong HuaYongfeng YuShun LuNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-8 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Hong Jian Wei Li Zhiyong Ma Jianjin Huang Jifeng Feng Yong Song Beili Gao Huili Zhu Min Tao Chong Bai Shenglin Ma Hongming Pan Shukui Qin Dong Hua Yongfeng Yu Shun Lu Intercalating and maintenance gefitinib plus chemotherapy versus chemotherapy alone in selected advanced non-small cell lung cancer with unknown EGFR status
description	Abstract Epidermal growth factor receptor tyrosine-kinase inhibitors (EGFR-TKIs) are standard treatment for advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation. However, EGFR mutation testing is not attainable in approximately 20% of patients. The current study examined intercalating and maintaining gefitinib treatment in stage IIIB/IV non-squamous NSCLC, never or former light smoking patients with unknown EGFR mutation status. Briefly, 219 patients who achieved stable disease (SD) with gemcitabine (1250 mg/m2) plus carboplatin (5 AUC) were randomized at 1:1 ratio to continue chemotherapy (n = 110) or intercalating gefitinib (250 mg/day on days 15–25 of each cycle until disease progress (n = 109). Progression-free survival (PFS) was 9.7 vs. 4.2 month in the gefitinib vs. control arm (HR: 0.41, 95% CI: 0.31–0.56; P < 0.001). Overall survival (OS) was also longer in the gefitinib arm (20.1 vs. 15.4 months; HR: 0.68; 95% CI 0.48–0.97; P = 0.0323). Adverse events, including diarrhea, dermal reaction and thrombocytopenia, were more common in the gefitinib arm. In conclusion, intercalating and maintenance gefitinib treatment is a viable option for advanced NSCLC patients with unknown EGFR mutation status in subpopulations with high EFGR mutation rate.
format	article
author	Hong Jian Wei Li Zhiyong Ma Jianjin Huang Jifeng Feng Yong Song Beili Gao Huili Zhu Min Tao Chong Bai Shenglin Ma Hongming Pan Shukui Qin Dong Hua Yongfeng Yu Shun Lu
author_facet	Hong Jian Wei Li Zhiyong Ma Jianjin Huang Jifeng Feng Yong Song Beili Gao Huili Zhu Min Tao Chong Bai Shenglin Ma Hongming Pan Shukui Qin Dong Hua Yongfeng Yu Shun Lu
author_sort	Hong Jian
title	Intercalating and maintenance gefitinib plus chemotherapy versus chemotherapy alone in selected advanced non-small cell lung cancer with unknown EGFR status
title_short	Intercalating and maintenance gefitinib plus chemotherapy versus chemotherapy alone in selected advanced non-small cell lung cancer with unknown EGFR status
title_full	Intercalating and maintenance gefitinib plus chemotherapy versus chemotherapy alone in selected advanced non-small cell lung cancer with unknown EGFR status
title_fullStr	Intercalating and maintenance gefitinib plus chemotherapy versus chemotherapy alone in selected advanced non-small cell lung cancer with unknown EGFR status
title_full_unstemmed	Intercalating and maintenance gefitinib plus chemotherapy versus chemotherapy alone in selected advanced non-small cell lung cancer with unknown EGFR status
title_sort	intercalating and maintenance gefitinib plus chemotherapy versus chemotherapy alone in selected advanced non-small cell lung cancer with unknown egfr status
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/73a535d20751439e9652e1984861c8ac
work_keys_str_mv	AT hongjian intercalatingandmaintenancegefitinibpluschemotherapyversuschemotherapyaloneinselectedadvancednonsmallcelllungcancerwithunknownegfrstatus AT weili intercalatingandmaintenancegefitinibpluschemotherapyversuschemotherapyaloneinselectedadvancednonsmallcelllungcancerwithunknownegfrstatus AT zhiyongma intercalatingandmaintenancegefitinibpluschemotherapyversuschemotherapyaloneinselectedadvancednonsmallcelllungcancerwithunknownegfrstatus AT jianjinhuang intercalatingandmaintenancegefitinibpluschemotherapyversuschemotherapyaloneinselectedadvancednonsmallcelllungcancerwithunknownegfrstatus AT jifengfeng intercalatingandmaintenancegefitinibpluschemotherapyversuschemotherapyaloneinselectedadvancednonsmallcelllungcancerwithunknownegfrstatus AT yongsong intercalatingandmaintenancegefitinibpluschemotherapyversuschemotherapyaloneinselectedadvancednonsmallcelllungcancerwithunknownegfrstatus AT beiligao intercalatingandmaintenancegefitinibpluschemotherapyversuschemotherapyaloneinselectedadvancednonsmallcelllungcancerwithunknownegfrstatus AT huilizhu intercalatingandmaintenancegefitinibpluschemotherapyversuschemotherapyaloneinselectedadvancednonsmallcelllungcancerwithunknownegfrstatus AT mintao intercalatingandmaintenancegefitinibpluschemotherapyversuschemotherapyaloneinselectedadvancednonsmallcelllungcancerwithunknownegfrstatus AT chongbai intercalatingandmaintenancegefitinibpluschemotherapyversuschemotherapyaloneinselectedadvancednonsmallcelllungcancerwithunknownegfrstatus AT shenglinma intercalatingandmaintenancegefitinibpluschemotherapyversuschemotherapyaloneinselectedadvancednonsmallcelllungcancerwithunknownegfrstatus AT hongmingpan intercalatingandmaintenancegefitinibpluschemotherapyversuschemotherapyaloneinselectedadvancednonsmallcelllungcancerwithunknownegfrstatus AT shukuiqin intercalatingandmaintenancegefitinibpluschemotherapyversuschemotherapyaloneinselectedadvancednonsmallcelllungcancerwithunknownegfrstatus AT donghua intercalatingandmaintenancegefitinibpluschemotherapyversuschemotherapyaloneinselectedadvancednonsmallcelllungcancerwithunknownegfrstatus AT yongfengyu intercalatingandmaintenancegefitinibpluschemotherapyversuschemotherapyaloneinselectedadvancednonsmallcelllungcancerwithunknownegfrstatus AT shunlu intercalatingandmaintenancegefitinibpluschemotherapyversuschemotherapyaloneinselectedadvancednonsmallcelllungcancerwithunknownegfrstatus
_version_	1718388962712616960

Intercalating and maintenance gefitinib plus chemotherapy versus chemotherapy alone in selected advanced non-small cell lung cancer with unknown EGFR status

Ejemplares similares